Conversion of Convertible Loan Notes
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Pharmaceuticals plc
(“Hemogenyx Pharmaceuticals” or the “Company”)
Conversion of Convertible Loan Notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received a conversion notice from Mint Capital Advisors Ltd (“Mint Capital”) in respect of £900,000 in principal amount of the Convertible Loan Notes issued by the Company on 3 February 2021.
Pursuant to the conversion, the Company will issue, in aggregate, 14,285,714 new ordinary shares of £0.01 each in the capital of the Company (the “New Ordinary Shares”) at a conversion price of £0.063 per Ordinary Share.
Application will be made to the Financial Conduct Authority and to the London Stock Exchange for the admission of the New Ordinary Shares to the standard segment of the Official List and to trading on the London Stock Exchange’s main market for listed securities, respectively (“Admission”). It is expected that Admission will occur at 8.00 a.m. on or around 6 April 2021. The New Ordinary Shares will rank pari passu with the existing issued Ordinary Shares in the Company.
The Company does not have any immediate plans for further drawdowns from the Convertible Notes Facility.
Total Voting Rights
Following Admission of the New Ordinary Shares, the Company will have 468,795,217 Ordinary Shares of £0.01 each in issue with voting rights. The Company does not hold any shares in treasury. This figure may then be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.
Unless defined herein, or the context requires otherwise, capitalised terms used in this announcement carry the same meaning as those ascribed to them in the Company’s announcement of 18 November 2020.
The person responsible for arranging for the release of this announcement on behalf of the Company is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
|Hemogenyx Pharmaceuticals plc||https://hemogenyx.com|
|Dr Vladislav Sandler, Chief Executive Officer & Co-Founderfirstname.lastname@example.org|
|Peter Redmond, Directoremail@example.com|
|SP Angel Corporate Finance LLP||Tel: +44 (0)20 3470 0470|
|Matthew Johnson, Vadim Alexandre, Adam Cowl|
|Peterhouse Capital Limited||Tel: +44 (0)20 7469 0930|
|Lucy Williams, Duncan Vasey, Charles Goodfellow|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company’s technology has the potential to enable many more patients suffering from devastating blood diseases such as leukaemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anaemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.